A Phase 3 interventional study of sitagliptin and liraglutide in Diabetes Mellitus, Type 2, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-06-09.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 20th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 97th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18–65
Bahria University · Sites in Pakistan
Ages 30–55
Yonsei University · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 11 · Phase 3 74 · Phase 4 68
First in 2003; this study’s year is marked. 13 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 653 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 102 across the 197 interventional studies. Of the 172 that completed or were terminated, 117 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 198 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 26th largest by enrollment of the 170 interventional ones that give a count, is one of 10 that started in 2011, is one of 86 in phase 3, and was the 113th registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with Type 2 Diabetes that is not adequately controlled with metformin alone. The primary hypothesis postulated that the mean change from baseline in hemoglobin A1c (A1C) in participants treated with a sitagliptin-based treatment is non-inferior to that of participants treated with a liraglutide-based
treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sitagliptin 100 mg tablet orally once daily for 26 weeks. Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have received glimepiride orally for glycemic control.
Drug: sitagliptin · Drug: glimepiride · Drug: metformin
Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
Drug: liraglutide · Drug: metformin
100 mg tablet, orally, once daily.
Also known as: MK-0431, Januvia®, Tesavel®, Xelevia®, Ristaben®
0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
Also known as: Victoza®
starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
Also known as: Amaryl®
metformin tablets at a dose of ≥1500 mg per day
Also known as: Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
Change From Baseline in Hemoglobin A1c (A1C)
A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.
Time frame: Baseline and Week 26
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline at Week 26 is defined as Week 26 minus Week 0.
Time frame: Baseline and Week 26
Percentage of Participants Reaching A1C Goal of <7.0%
Time frame: Week 26
Percentage of Participants Reaching A1C Goal of <6.5%
Time frame: Week 26
| Milestone | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| Started | 326 | 327 |
| Completed | 275 | 257 |
| Not completed | 51 | 70 |
| Withdrew: Adverse event | 8 | 29 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 10 | 7 |
| Withdrew: Non-compliance with study drug | 1 | 2 |
| Withdrew: Other reason not specified | 20 | 15 |
| Withdrew: Physician decision | 1 | 3 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 10 | 13 |
A1C is measured as percent. Thus, this change from baseline reflects the Week 26 A1C percent minus the Week 0 A1C percent.
| percent | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (A1C) | -1.32 ± 1.06 | -1.42 ± 1.04 |
Change from baseline at Week 26 is defined as Week 26 minus Week 0.
| mg/dL | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -33.7 ± 46.2 | -39.6 ± 40.3 |
| percentage of participants | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| Percentage of Participants Reaching A1C Goal of <7.0% | 62.8 | 72.3 |
| percentage of participants | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| Percentage of Participants Reaching A1C Goal of <6.5% | 33.8 | 38.3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sitagliptin +/- Glimepiride | — | 17/326 (5.2%) | 58/326 (17.8%) |
| Liraglutide | — | 12/324 (3.7%) | 97/324 (29.9%) |
| Event | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 2/326 | 0/324 |
| Non-cardiac chest painGeneral disorders | 1/326 | 1/324 |
| Prostatic specific antigen increasedInvestigations | 0/326 | 1/324 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/326 | 1/324 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 0/326 | 1/324 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/326 | 1/324 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/326 | 1/324 |
| EncephalopathyNervous system disorders | 0/326 | 1/324 |
| SciaticaNervous system disorders | 0/326 | 1/324 |
| Transient ischaemic attackNervous system disorders | 0/326 | 1/324 |
| Event | Sitagliptin +/- Glimepiride | Liraglutide |
|---|---|---|
| NauseaGastrointestinal disorders | 10/326 | 63/324 |
| HypoglycaemiaMetabolism and nutrition disorders | 41/326 | 15/324 |
| DiarrhoeaGastrointestinal disorders | 7/326 | 35/324 |
| VomitingGastrointestinal disorders | 6/326 | 21/324 |
| Decreased appetiteMetabolism and nutrition disorders | 4/326 | 21/324 |
| Age, Continuous(years) | Sitagliptin +/- Glimepiride | Liraglutide | Total |
|---|---|---|---|
| Mean | 56.9 ± 10.0 | 57.6 ± 10.8 | 57.3 ± 10.4 |
| Sex: Female, Male(Participants) | Sitagliptin +/- Glimepiride | Liraglutide | Total |
|---|---|---|---|
| Female | 148 | 147 | 295 |
| Male | 178 | 180 | 358 |
| Hemoglobin A1c (A1C)(Percent) | Sitagliptin +/- Glimepiride | Liraglutide | Total |
|---|---|---|---|
| Mean | 8.2 ± 1.1 | 8.1 ± 0.9 | 8.2 ± 1.0 |
| Fasting Plasma Glucose(mg/dL) | Sitagliptin +/- Glimepiride | Liraglutide | Total |
|---|---|---|---|
| Mean | 174.1 ± 43.7 | 172.9 ± 40.8 | 173.5 ± 42.3 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
Ran from Mar 2011 to primary completion in Feb 2012, 11 months.
Results were first posted in Mar 2013, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 11 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sitagliptin